BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
66.89
-0.13 (-0.19%)
Dec 27, 2024, 4:00 PM EST - Market closed
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,401 employees as of December 31, 2023. The number of employees increased by 319 or 10.35% compared to the previous year.
Employees
3,401
Change (1Y)
319
Growth (1Y)
10.35%
Revenue / Employee
$809,412
Profits / Employee
$94,764
Market Cap
12.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Tenet Healthcare | 106,500 |
Universal Health Services | 96,700 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 27,048 |
Revvity | 11,500 |
Incyte | 2,524 |
Genmab | 2,204 |
BMRN News
- 5 weeks ago - Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call - Seeking Alpha
- 5 weeks ago - BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 - PRNewsWire
- 7 weeks ago - BioMarin to Participate in Three Upcoming Investor Conferences - PRNewsWire
- 2 months ago - BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook - PRNewsWire
- 2 months ago - BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET - PRNewsWire
- 2 months ago - 3 Oversold Stocks with Big RSI Rebound Potential - Benzinga
- 3 months ago - BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish - Benzinga